DUBLIN–(BUSINESS WIRE)–The “Erythropoietin Drugs Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2028” report has been added to ResearchAndMarkets.com’s offering.
The global erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.
The rise in number of patients suffering from anemic conditions induced due to cancer, HIV and ESRD treatment, favorable reimbursements, and increase in commercialization of EPO biosimilars are the major factors for the market growth.
However, side effects such as arterial hypertension, iron deficiency, influenza-like syndrome, and longer treatment period (4-6 weeks) hampers growth of erythropoietin drugs market.
Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth. Furthermore, commercialization patterns for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and awareness regarding benefits of EPO therapeutics contribute toward growth of erythropoietin drugs market.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of erythropoietin used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Topics Covered
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Clinical Trials for EPO Drug
3.3. Market Share Analysis, 2020
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increasing Number Cases: Including Cancer, HIV, Kidney Disease and Anemia
3.4.1.2. Growing Trends of Commercialization for Erythropoietin Biosimilars
3.4.1.3. Increasing Level of Awareness About the Benefits of EPO Therapeutics
3.4.2. Restraints
3.4.2.1. Unaffordability of Therapeutics
3.4.2.2. Longer Duration of Treatments
3.4.2.3. Adverse Amount of Side Effects
3.4.3. Opportunities
3.4.3.1. Commercialization of Darbepoetin Alfa Biosimilar
3.4.3.2. Achieving Economies of Scale Across Developed Region with Biosimilar Version of EPO
3.5. Impact of COVID-19 on the Market
Chapter 4: Global Erythropoietin Market by Products
4.1. Epoetin-Alfa
4.2. Epoetin-Beta
4.3. Darbepoetin-Alfa
4.4. Other
Chapter 5: Global Erythropoietin Market by Applications
5.1. Hematology
5.2. Kidney Disorders (ESRD & Dialysis)
5.3. Cancer
5.4. Others
Chapter 6: Global Erythropoietin Market by Geography
6.1. North America
6.2. Europe
6.3. Asia-Pacific
6.4. LAMEA
Chapter 7: Company Profiles
7.1. Amgen Inc.
7.2. Johnson & Johnson
7.3. Roche Diagnostics
7.4. Hospira Inc.
7.5. LG Life Sciences Ltd.
7.6. Biocon
7.7. Intas Pharmaceuticals
7.8. Teva Pharmaceutical Industries Ltd.
7.9. Ranbaxy Laboratories Ltd.
7.10. Celltrion, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/av2cz8
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900